D-Gluconic acid calcium salt

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-Gluconic acid calcium salt
• 英文别名: calcium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
• 化学式: C12H22CaO14
• 分子量: 430.37
• InChiKey: NEEHYRZPVYRGPP-IYEMJOQQSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -10.04
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  283
• 氢给体数：
  10
• 氢受体数：
  14

ADMET

代谢

葡萄糖酸钙在释放Ca++方面不需要经过肝脏代谢，在肝功能缺失的情况下，治疗离子低钙血症的效果与氯化钙相当。

Calcium gluconate does not require hepatic metabolism for the release of Ca++ and is as effective as calcium chloride in treating ionic hypocalcemia in the absence of hepatic function.

来源:DrugBank

毒理性

• 眼睛症状

Redness.

Redness.

来源:ILO-WHO International Chemical Safety Cards (ICSCs)

毒理性

• 相互作用

过量同时使用酒精、咖啡因（通常指每天超过8杯咖啡）或烟草已被报道会减少钙的吸收。

Concurrent use of excessive amounts of /alcohol, caffeine (usually more than 8 cups of coffee a day), or tobacco/ has been reported to decrease calcium absorption.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

同时使用雌激素和钙补充剂可能会增加钙的吸收，这在雌激素被开用于治疗绝经后骨质疏松症时，被用作治疗上的优势。钙补充剂。

Concurrent use /of estrogens/ with calcium supplements may increase calcium absorption, which is used to therapeutic advantage when estrogens are prescribed for the treatment of postmenopausal osteoporosis. /Calcium supplements/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

与钙补充剂同时使用可能会降低纤维素钠磷酸盐预防高钙尿症的有效性。/钙补充剂/

Concurrent use with calcium supplements may decrease effectiveness of cellulose sodium phosphate in preventing hypercalciuria. /Calcium supplements/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

与其他含有钙的药物或口服含镁的药物同时使用，可能会增加易感患者（主要是肾功能受损的患者）的血清钙或镁浓度，分别导致高钙血症或高镁血症。/钙补充剂/

Concurrent use /of other calcium-containing medications or oral magnesium-containing medications/ with calcium supplements may increase serum calcium or magnesium concentration in susceptible patients, mainly patients with impaired renal function, leading to hypercalcemia or hypermagnesemia, respectively. /Calcium supplements/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

• 吸收

大约五分之一到三分之一的口服钙在小肠中被吸收，这取决于维生素D代谢物、肠腔内的pH值以及饮食因素，如钙与纤维或植酸的结合。当存在钙缺乏或患者处于低钙饮食时，钙的吸收会增加。在患有胃酸过少或低胃酸的患者中，尤其是使用碳酸盐形式的钙时，钙的吸收可能会减少。

Approximately one-fifth to one-third of orally administered calcium is absorbed in the small intestine, depending on presence of vitamin D metabolites, pH in lumen, and on dietary factors, such as calcium binding to fiber or phytates. Calcium absorption is increased when a calcium deficiency is present or when a patient is on a low-calcium diet. In patients with achlorhydria or hypochlorhydria, calcium absorption, especially with the carbonate salt, may be reduced.

来源:DrugBank

吸收、分配和排泄

• 消除途径

肾脏（20%）- 尿液中排出的量随钙的吸收程度以及是否存在过度骨丢失或肾脏保存功能失败而变化。粪便（80%）- 主要由未被吸收的钙组成，只有少量的内源性粪便钙被排出。

Renal (20%) - The amount excreted in the urine varies with degree of calcium absorption and whether there is excessive bone loss or failure of renal conservation. Fecal (80%) - Consists mainly of nonabsorbed calcium, with only a small amount of endogenous fecal calcium excreted.

来源:DrugBank

吸收、分配和排泄

• 分布容积

没有可用的信息。

Not available

来源:DrugBank

吸收、分配和排泄

大约五分之一到三分之一的口服钙在小肠中被吸收，这取决于维生素D代谢物、肠腔内的pH值以及饮食因素，比如钙与纤维或植酸的结合。当存在钙缺乏或患者处于低钙饮食时，钙的吸收会增加。在患有胃酸过少或低胃酸的患者中，尤其是使用碳酸盐形式的钙时，钙的吸收可能会减少。/钙补充剂/

Approximately one-fifth to one-third of orally administered calcium is absorbed in the small intestine, depending on presence of vitamin D metabolites, pH in lumen, and on dietary factors, such as calcium binding to fiber or phytates. Calcium absorption is increased when a calcium deficiency is present or when a patient is on a low-calcium diet. In patients with achlorhydria or hypochlorhydria, calcium absorption, especially with the carbonate salt, may be reduced. /Calcium supplements/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

消除：肾脏（20%）- 尿液中排出的量随钙吸收程度以及是否存在过度骨丢失或肾脏保存功能失败而变化。粪便（80%）- 主要由未被吸收的钙组成，只有少量内源性粪便钙被排出。/钙补充剂/

Elimination: Renal (20%) - The amount excreted in the urine varies with degree of calcium absorption and whether there is excessive bone loss or failure of renal conservation. Fecal (80%) - Consists mainly of nonabsorbed calcium, with only a small amount of endogenous fecal calcium excreted. /Calcium supplements/

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  2-羟基丙酸钙盐 、 D-Gluconic acid calcium salt 在 乙醇 作用下， 以 水 为溶剂， 生成 calcium;2-hydroxypropanoate;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
  参考文献：
  名称：

  Preparation of calcium fortified powdered milk products with improved

  摘要：

  本发明涉及一种具有在水介质中改善分散性的钙强化粉状牛奶产品及其生产过程。该过程通常包括将牛奶产品与钙强化系统混合以形成钙强化混合物；将该钙强化混合物冷却至有效启动乳糖结晶的温度；并脱水该钙强化混合物以获得具有在水介质中改善分散性的钙强化干奶粉。

  公开号：

  US05397589A1
• 作为产物：
  描述：

  D-gulopyranose 、 calcium carbonate 以86%的产率得到
  参考文献：
  名称：

  MEHA, ANITA;PUROHIT, D. N.;MISRA, R. A., ORIENTAL J. CHEM., 5,(1989) N, C. 304-309

  摘要：

  DOI：

文献信息

• [EN] PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PRMT5 CONTENANT UNE DIHYDRO- OU TÉTRAHYDRO-ISOQUINOLÉINE ET LEURS UTILISATIONS
  申请人：EPIZYME INC

  公开号：WO2014100730A1

  公开（公告）日：2014-06-26

  Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

  本文描述了式（A）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• PRMT5 INHIBITORS AND USES THEREOF
  申请人：Duncan Kenneth W.

  公开号：US20190083482A1

  公开（公告）日：2019-03-21

  Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

  本文描述了式（I）的化合物，其药学上可接受的盐以及药物组合物。本发明的化合物对抑制PRMT5活性是有用的。还描述了利用这些化合物治疗PRMT5介导的疾病的方法。
• Controlled-release compositions containing opioid agonist and antagonist
  申请人：——

  公开号：US20020010127A1

  公开（公告）日：2002-01-24

  Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.

  含有阿片激动剂、阿片拮抗剂和受控释放材料的控释剂型，其在给药间隔期间释放阿片激动剂的镇痛或亚镇痛量以及足以减轻所述阿片激动剂的副作用的阿片拮抗剂的量。当给予人类患者时，该剂型提供至少约8小时的镇痛作用。在其他实施例中，给药间隔期释放的拮抗剂剂量增强了阿片激动剂的镇痛效力。
• 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267689A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I): wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明涵盖了以下式（I）的化合物： 其中：X，R1，R2，R3和R4如规范中所定义。该发明还涵盖了一种预防、治疗或改善综合征、疾病或疾病的方法，其中所述综合征、疾病或疾病是II型糖尿病、肥胖和哮喘。该发明还涵盖了通过给哺乳动物施用至少一种式（I）化合物的治疗有效量来抑制CCR2活性的方法。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE POUR LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2017205538A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders such as cancer, inflammatory disorders and autoimmune diseases.

  本发明涉及一种化合物公式（I）及其盐，其中R1、R2X和Y具有本文中定义的任何值，以及其组合物和用途。这些化合物可用作CBP和/或EP300的抑制剂。还包括包含公式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的疾病，如癌症、炎症性疾病和自身免疫疾病中使用这些化合物和盐的方法。

表征谱图